{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:45:16Z","timestamp":1790959516505,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010345","name":"B. Braun-Stiftung","doi-asserted-by":"publisher","award":["BBST\u2010D\u201021\u201000027"],"award-info":[{"award-number":["BBST\u2010D\u201021\u201000027"]}],"id":[{"id":"10.13039\/100010345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["455749974"],"award-info":[{"award-number":["455749974"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug\u2013drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted. The aim of this work was to validate pantoprazole as a CYP2C19 phenotyping drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a single\u2010dose pharmacokinetic study with 20 healthy participants in a randomized cross\u2010over design. Participants received 10\u00a0mg omeprazole and 20\u2009mg pantoprazole on two different study days with a washout phase of one week. Blood sampling was performed at 14 time points spanning 8\u00a0h after drug administration. Drug and metabolite plasma concentrations were assessed by LC\u2013MS\/MS. Metabolic ratios (MR) of metabolite\/substrate were formed using the area under the curve from 0 to 8\u00a0h (AUC\n                      <jats:sub>0\u20108h<\/jats:sub>\n                      ) and single plasma concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We demonstrate very strong correlations (Spearman \u03c1\u2009=\u00a00.84) of AUC\n                      <jats:sub>0\u20108h<\/jats:sub>\n                      MR 4\u2010desmethylpantoprazole\u2010sulfate\/pantoprazole to the validated CYP2C19 probe AUC\n                      <jats:sub>0\u20108h<\/jats:sub>\n                      MR 5\u2010hydroxyomeprazole\/omeprazole (Spearman \u03c1\u2009= 0.84). Single time point pantoprazole MRs measured in plasma between 4 and 8\u00a0h after pantoprazole administration were sufficient for accurate CYP2C19 phenotyping by demonstrating significant and robust correlations to the AUC\n                      <jats:sub>0\u20108h<\/jats:sub>\n                      MR 5\u2010hydroxyomeprazole\/omeprazole with Spearman \u03c1\u2009\u2265\u00a00.8.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In contrast to omeprazole, pharmacokinetics of pantoprazole are described to be stable during repeated dosing, which may allow phenotyping of CYP2C19 with patients using pantoprazole MRs in situations where pantoprazole is part of the prescribed medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70631","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T23:24:27Z","timestamp":1780269867000},"page":"3387-3396","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of a pantoprazole and 4\u2010desmethylpantoprazole\u2010sulfate metabolic ratio as a novel CYP2C19 phenotyping method"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1505-5664","authenticated-orcid":false,"given":"Julian Peter","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Belov","sequence":"additional","affiliation":[{"name":"Department of NanoBiophotonics Max Planck Institute for Multidisciplinary Sciences (MPI\u2010NAT)  G\u00f6ttingen Lower Saxony Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Yamoune","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Miller","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Hasoumi","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Tupiec","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Laurentius","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"},{"name":"Department of Geriatrics Carl von Ossietzky University of Oldenburg  Oldenburg Lower Saxony Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Cornelius","family":"Bollheimer","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Stingl","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"},{"name":"Department of Clinical Pharmacology and Pharmacoepidemiology University Hospital Heidelberg  Heidelberg Baden\u2010W\u00fcrttemberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8078","authenticated-orcid":false,"given":"Katja S.","family":"Just","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital RWTH Aachen  Aachen North Rhine\u2010Westphalia Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2017.12.001"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3378"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1326776"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008327537"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2146"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2412"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2017.03.001"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040593"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010019\u201000783\u2010z"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000991"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/23333928241241220"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2003.10.010"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12667"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.289"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14157"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1201906"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14267"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1949"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010025\u201002872\u20105"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000059157.46867.42"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041293"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.219"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1088\/1752\u20107163\/10\/4\/046017"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102036.2000.00806.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010012\u20101252\u20103"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.030601"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.147751"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13232"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.225680"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360\u2010020\u201000433\u20102"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.83"},{"key":"e_1_2_10_33_1","unstructured":"European Medicines Agency.VICH GL52 Bioequivalence: blood level bioequivalence study. Updated 2015\/09\/17. Accessed May 8 2026https:\/\/www.ema.europa.eu\/en\/vich-gl52-bioequivalence-blood-level-bioequivalence-study-scientific-guideline"},{"key":"e_1_2_10_34_1","unstructured":"Clinical Pharmacogenetics Implementation Consortium.CPIC\u00ae Guideline for Clopidogrel and CYP2C19. Updated January 2022. Accessed July 8 2025.https:\/\/cpicpgx.org\/guidelines\/guideline-for-clopidogrel-and-cyp2c19\/"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2526"},{"issue":"5","key":"e_1_2_10_36_1","first-page":"185","article-title":"Pharmacokinetics of pantoprazole in man","volume":"34","author":"Huber R","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_10_37_1","unstructured":"GurjarMK TripathyNK MaikapGS et al.Pyridone Derivatives As Acid Secretion Inhibitors And Process For Preparation Thereof. Patent No. US20150232467A1.2015August 20."},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0968\u20100896(02)00237\u20107"},{"key":"e_1_2_10_39_1","unstructured":"Rajnikant VyasJ Mallik YadavK Dishman Pharmaceuticals and Chemicals Ltd.A Preparation Method For Substituted 2\u2010(2\u2010Pyridilmethoylsulphinyl)\u20101\u2010H\u2010Benzimid Azoles. Patent No. WO2006\/049486 A1. May 11 2006"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010025\u201004145\u20106"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16176"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272\u2010023\u201001478\u20107"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.5.729"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16113"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010021\u201003257\u2010z"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2024.121596"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010023\u201003534\u2010z"},{"key":"e_1_2_10_49_1","unstructured":"European Medicines Agency.Pantozol Control: EPAR \u2010 Product Information. Updated May 25 2023. Accessed November 3 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pantozol-control-epar-product-information_en.pdf"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010377501"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010200363010\u201000006"},{"issue":"10","key":"e_1_2_10_52_1","first-page":"415","article-title":"Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers","volume":"34","author":"Tanaka M","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103349"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70631","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70631","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:56:10Z","timestamp":1790618170000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/bcp.70631"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70631","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}